Cowen & Co
http://www.cowen.com/default.htmlCowen and Company offers investment banking services, including equity research, equity and convertible debt financings, mergers and acquisitions advisory services, and restricted security sales.
-
Mugglehead reveals a number of stocks set to take advantage of hemp
-
Mugglehead reveals a number of stocks set to take advantage of hemp
-
GW Pharmaceuticals plc Announces the Closing of Public Offering of ADSs, Raising Gross Proceeds of $345 Million and Full Exercise of Underwriters' Option to Purchase Additional ADSs
-
GW Pharma (GWPH) Prices 1.9M ADS Public Offering at $158/ADS
-
GW Pharmaceuticals plc Announces Pricing of Public Offering of ADSs Raising Gross Proceeds of $300 Million
-
GW Pharma (GWPH) Announces Proposed $300M Public Offering of ADSs
-
GW Pharmaceuticals Announces Proposed Public Offering of ADSs
-
GW Pharma (GWPH): Benign Briefing Docs Support Epidiolex Approval - Cowen
-
GW Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference on 12 March
-
GW Pharmaceuticals plc Announces the Closing of Public Offering of ADSs Raising Gross Proceeds of $317.4 Million and Full Exercise of Underwriter’s Option to Purchase Additional ADSs
-
GW Pharma (GWPH) Prices 2.4M ADS Offering at $115/Sh
-
GW Pharmaceuticals plc Announces Pricing of Public Offering of ADSs Raising Gross Proceeds of $276 Million
-
GW Pharma (GWPH) to Offer $225M in ADSs
-
GW Pharmaceuticals Announces Proposed Public Offering of ADSs
-
GW Pharma (GWPH) Defended at Cowen; Epidiolex Opportunity Largely Unaffected by ZX008
-
GW Pharmaceuticals to Present at the Cowen and Company 37th Annual Healthcare Conference on Wednesday, 8 March, 2017
-
Legal Pot Business Could Get a Big Jolt on Path to $50B Industry
-
GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising $289.8 Million on the NASDAQ Global Market and Full Exercise of Underwriter’s Option
-
GW Pharma (GWPH) Prices 2.8M Share Offering at $90/ADS
-
GW Pharmaceuticals plc Announces Pricing of U.S. Public Offering of ADSs Raising $252.0 Million on NASDAQ Global Market
-
GW Pharmaceuticals (GWPH) to Offer $150M in ADSs
-
GW Pharmaceuticals Announces Proposed Public Offering of ADSs
-
GW Pharma (GWPH) Was Never Registered to Present at Conference - Bloomberg, Citing Cowen
-
GW Pharma (GWPH) Said to Cancel Out of Upcoming Conf. Ahead of Epidiolex Phase 3 Data Release
-
Pre-Open Stock Movers 12/24: (PN) (GWPH) (SUNE) Higher; (RVNC) (CALM) (NSC) Lower (more...)
-
Streetinsider.com's Hot Lunchtime Reads 9/15: (TGT) (ALNY) (RAI) (FB) (GWPH)
-
Cowen Reiterates Bullish View on GW Pharma (GWPH) Post Q3; Says All Eyes on Epilepsy Pivotal Data In Early Q1:16
-
Fresh Off Generic Sale, Allergan (AGN) is Poised for Merger of Epic Proportions (AMGN) (ABBV)
-
Cowen Remains Bullish on GW Pharma (GWPH) Following Epilepsy Symposium in NYU
-
GW Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
-
GW Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
-
GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately $179.2 Million on the NASDAQ Global Market
-
GW Pharmaceuticals plc Announces Pricing of U.S. Public Offering of ADSs Raising $179.2 Million on NASDAQ Global Market
-
GW Pharma (GWPH) to Offer 1.25M ADSs
-
GW Pharmaceuticals Announces Proposed Public Offering of ADSs
-
GW Pharmaceuticals Announces Proposed Public Offering of ADSs
-
GW Pharma (GWPH) 1.7M Secondary Offering Prices at $86.83/ADS
-
GW Pharma (GWPH) Prices 1.7M Offering at $86.83/ADS
-
GW Pharma (GWPH) Announces 1.7M ADS Offering
-
GW Pharmaceuticals (GWPH) Files for Follow-On Common Offering
-
Unusual 11 Mid-Day Movers 10/03: (OINK) (GWPH) (OMER) Higher; (CEVA) (ANGI) (TXI) Lower

